対面式グループディスカッション

対面式グループディスカッションは、参加者がアイデアや経験を交換し、焦点を絞ったトピックについて将来のコラボレーションを発展させるための非公式な承認制のディスカッションです。各ディスカッションは、ファシリテーターによって進行され、トラックとグループ参加のディスカッションを管理します。この形式を最大限に活用するために、業務における実例を共有し、グループの一員となり、問題解決セッションや活発なアイデアの共有への参加に向けご準備ください。

2023年のコンテンツトピックについては、7月に当ページをご覧ください。

水曜日のダイバーシティに関するディスカッションを含む全グループディスカッションは、対面でのみ提供されます。

パート A カンファレンス: 9月26日（火）, 2:50-3:35 PM

Protein Degraders and Molecular Glues - Part 1
プロテインデグレーダーと分子接着剤　パート1
New Chemistries and Assays for Next-Generation Degraders and Glues

Moderators:
Rima Al-Awar, PhD, Head, Therapeutic Innovation & Drug Discovery, Ontario Institute for Cancer Research
Benedict Cross, PhD, CTO, PhoreMost Ltd.
Daniel A. Erlanson, PhD, Senior Vice President, Innovation and Discovery, Frontier Medicines Corporation

• Leveraging covalent chemistry, induced proximity to develop new degrader modalities
• Utilizing new assays and platforms for structural and mechanistic characterization
• Finding new ligases and cellular pathways for inducing degradation
• Pursuing degradation as a strategy for important therapeutic targets

Proteomics-Driven Drug Discovery
プロテオミクスによる創薬
Leveraging Phenotypic Screening, Chemical Biology, and Chemoproteomics Tools

Moderators:
Gizem Akcay, PhD, Head, Chemical Biology, Bayer Research and Innovation Center Cambridge
Christopher am Ende, PhD, Associate Research Fellow, Internal Medicine Medicinal Chemistry, Pfizer Inc.
Steve Gygi, PhD, Professor, Department of Cell Biology, Harvard Medical School
Andrew Zhang, PhD, Director, Chemical Biology, AstraZeneca

• How can proteomics be best used in the drug discovery pipeline?
• Can traditional chemoproteomics and orthogonal methods help deconvolute “undruggable” targets?
• Which improvements are most needed in developing good proteomic assays and screening platforms?
• Insights into some of the new chemistries and chemical probes being generated

Small Molecules Targeting RNA
RNAを標的とする低分子
Challenges and Opportunities in Pursuing RNA as a Drug Target

Moderators:
Brahma Ghosh, PhD, Senior Principal Scientist & Head, Chemical Biology, Global Discovery Chemistry, Janssen Research & Development, LLC
Rabia Khan, PhD, MBA, CEO, Serna Bio
Alexander Serganov, PhD, Associate Professor, Department of Biochemistry & Molecular Pharmacology, New York University School of Medicine

• Emerging techniques for probing and modulating RNA
• Co-relating RNA binding with function and physiological response
• Rules for designing focused chemical libraries for targeting RNA/RNA-binding proteins
• Designing and optimizing small molecules targeting various RNA moieties
• Leveraging AI/ML, RNA degradation tools, and other drug development strategies

Small Molecules for Cancer Targets - Part 1
がん標的の低分子　パート1
Lead Generation for Small Molecule Cancer Targets

Moderator: Chaohong Sun, PhD, Senior Director, Lead Discovery, AbbVie, Inc.

• Lightning-round group member intros
• Favorite biophysical tools
• Integrating info from FBDD, DEL, HTS campaigns

Focusing on the Tumor Micro-Environment (TME)

Moderator: Scott Turner, PhD, Senior Vice President, Translational Sciences, Pliant Therapeutics

• Lightning-round group member intros
• Role of extra-cellular matrix (ECM)
• Relationship to fibrosis
• Relevance to metastasis

GPCR-Based Drug Discovery
GPCRベースの創薬
Finding GPCRs' Greatest Hits

Moderators:
Elisa Barile, PhD, Principal Scientist, Structural Biology & Biophysics, Takeda, San Diego
Phillip Schwartz, PhD, Director, Biophysics, Septerna

• Favorite new tools & technologies
• What’s your first step in GPCR-Targeted Drug Discovery?
• Lightning-round participant introductions

Antibodies Against Membrane Protein Targets - Part 1
抗膜タンパク質抗体の標的　パート1
Membrane Protein Discovery Challenges

Moderator: Noel T. Pauli, PhD, Group Leader, Antibody Engineering, Adimab LLC

• What are the challenges of working with in vitro and in vivo systems for membrane protein discovery?
• How can these approaches be effectively leveraged to identify antibodies targeting membrane proteins?
• What approaches are able to overcome typical hurdles that prevent efficient antibody affinity optimization against membrane protein targets?
• What technologies can be used to target specific epitopes on membrane proteins?

Current and Future Perspectives for in vivo Lead Generation and Screening Strategies towards Complex Membrane Protein Targets

Moderator: Alec Woosley, PhD, Senior Scientist, Biologics Engineering and Oncology R&D, AstraZeneca

• Encapsulated oligonucleotide-based immunization strategies for lead discovery and when to use what (DNA, mRNA, etc.)
• Virus-Like Particle (VLP) engineering and strategies for in vitro/vivo discovery workflows
• Divergent/engineered species for in vivo immunization workflows
• In vivo strategies combining formats for in vivo discovery and subsequent screening strategies
• Future of membrane protein formats and AI-based in silico design of membrane protein scaffolds for platform development

AI/ML-Enabled Drug Discovery - Part 1
AI/MLによる創薬　パート1
How Successful Are AI/ML Approaches in Drug Development Today?

Moderators:
Shruthi Bharadwaj, PhD, Global Lead, Digital & Analytics, R&D Global Operations, Sanofi
Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC

• Growing use of natural language processing, ChatGPT, and other tools
• Case studies highlighting use of knowledge graphs and quantum computing in healthcare
• Applying statistics, decision tree-based ML to data analysis in drug discovery
• Effective use of virtual screening and structure-activity predictions tools

パート A カンファレンス: 9月27日（水）, 8:30-9:00 AM

Neurodegeneration Targets
神経変性の標的
Early Discovery in Neurodegeneration

Moderators:
Jeffrey Martin, PhD, Scientist II, Drug Discovery, Biogen
Laura Silvian, PhD, Senior Director, Physical Biochemistry, Biogen

• Speed introductions
• Promising biomarkers for early-stage research
• Popular animal models

Translational Challenges in Neurodegeneration

Moderator: Kevin W. Hunt, PhD, CEO, Vanqua Bio

• Speed introductions
• Current models for CNS diseases
• iPSC systems
• PK/PD relationships

パート B カンファレンス: 9月27日（水）, 5:05-6:00 PM

Diversity Discussion
ダイバーシティ・ディスカッション
Embracing All Shades of Diversity

Join us for this interactive, informal, candid 55-minute discussion on welcoming and increasing all aspects of diversity in the life sciences. We have invited some engaging speakers to share their stories and experiences on initiatives that have and haven’t worked. Our goal is to help the audience learn, question, and get motivated to improve diversity in their own environments. This discussion will not be recorded nor available for on-demand access.

Topics for discussion will include, but certainly not be limited to:

• Creating avenues for improving gender diversity and participation
• Increasing racial diversity, particularly in leadership positions
• Reaching low income and underprivileged neighborhoods to eliminate any “zipcode bias”
• Understanding and addressing other hidden barriers and biases
• Implementing mentorship and internship programs that are simple yet impactful

パート B カンファレンス: 9月28日（木）, 10:05-10:50 AM

Protein Degraders and Molecular Glues - Part 2
プロテインデグレーダーと分子接着剤　パート2
Addressing the Translational Challenges Associated with Degraders & Glues

Moderators:
Simon Bailey, PhD, MBA, Executive Vice President & Head of Drug Discovery, Plexium, Inc.
Jin Wang, PhD, Professor, Pharmacology & Chemical Biology, Baylor College of Medicine

• Designing and optimizing modalities that are likely to succeed in the clinic
• Discussion of experimental and computational approaches helping translational research
• Developing assays that are sensitive and unbiased in finding the right targets and molecules
• Expanding the current toolbox to find new ligases and pathways for therapeutic intervention

Genomics-Driven Drug Discovery
ゲノミクスによる創薬
When and How to Best Leverage Genomics Tools and Data

Moderators:
William Chen, MD, PhD, Assistant Professor, Sanford School of Medicine, University of South Dakota
Nathan Lazar, PhD, Senior Director, Data Science, Recursion Pharmaceuticals, Inc.
Sarra Merzouk, PhD, Screening Staff Scientist, Genetic Perturbation Platform, Broad Institute of MIT and Harvard

• Expanding the current functional genomics toolbox for drug discovery
• Highlighting how CRISPR and base editor screens can be effectively used
• Leveraging genomic data to understand drug mechanisms and off-target effects
• Combining genomics and AI to help improve speed and accuracy
• Using synthetic biology for programmable genetic regulation

Targeting Transcription Factors
標的転写因子
Challenges and Opportunities in Pursuing Transcription Factors

Moderators:
Rhushikesh Kulkarni, PhD, Principal Scientist, Oncology Chemical Biology, Pfizer Inc.
Asad Taherbhoy, PhD, Director, Drug Discovery, Foghorn Therapeutics
William Tansey, PhD, Ingram Professor of Cancer Research, Professor of Cell & Development Biology, Vanderbilt University

• Assays and screening strategies to identify modulators of transcription factors
• Structural and mechanistic approaches for understanding mechanism of action
• Emerging transcription factors as viable drug targets for the various indications
• Designing potent, orally bioavailable drugs that target co-activators and inhibitors
• Pursuing degradation as a therapeutic strategy for targeting transcription factors

Small Molecules for Cancer Targets - Part 2
がん標的の低分子　パート2
Challenges Targeting Intracellular Oncoproteins

Moderator: Charles Wartchow, PhD, Associate Director, Global Discovery Chemistry, Novartis Institutes for BioMedical Research

• Why so many TPD approaches are for cancer
• Small molecule IO opportunities/combos
• Small Molecules in a Big Way: bRo5 issues
• Digging deeper: additional Q&A for Session Speakers

Fibrosis and Inflammation
線維症と炎症
Drug Development Challenges for Anti-Fibrotics

Moderators:
Cory M. Hogaboam, PhD, Professor, Medicine, Cedars-Sinai Medical Center; CSO, Lung Therapeutics
Vanessa M. Morales-Tirado, PhD, Principal Research Scientist I, Discovery Dermatology, Abbvie Bioresearch Center

• Quantifying fibrosis: markers for initial diagnosis
• Measuring treatment response
• Which is best for what?: AI, imaging, lab tests, histology scoring, more?
• Digging deeper: more Speaker Q&A

Lead Generation Strategies
リードジェネレーション戦略
DNA-Encoded Libraries (DELs) for Lead Discovery

Moderators:
Rachael Jetson, PhD, Senior Director, Lead Discovery, Valo Health
Douglas J Marcotte, Director, Protein Science, Valo Health

• Protein quality in DEL; what have we learned?
• Moving into the perceived ‘unDELable’ targets (RNAs, GPCRs, cellular, etc.); what are the current advances/thoughts?
• Making the most of your DEL platform by focusing on library design and selection conditions

Antibodies Against Membrane Protein Targets - Part 2
抗膜タンパク質抗体の標的　パート2
Avoiding Roadblocks: Maneuvering the Challenges of Difficult Targets

Moderator: Ross Chambers, PhD, Vice President Antibody Discovery, Antibody Discovery, Integral Molecular, Inc.

• Antigen design: antigen strategies and engineering for optimal target presentation
• Antibody sources: pros and cons of naive and immune libraries, and the benefits of using divergent species for targets that are highly conserved
• Screening: best approaches to identify diverse antibody panels, and merits of B cell cloning vs. display technologies
• Specificity: how to assess off-target binding

AI/ML-Enabled Drug Discovery - Part 2
AI/MLによる創薬　パート2
Leveraging AI/ML for Finding New Drug Targets and Leads

Moderators:
Anthony Bradley, PhD, Vice President, Design Development, Exscientia
Joseph Carpenter, PhD, Vice President, Medicinal Chemistry, Recursion Pharmaceuticals
Victor Guallar, PhD, Professor, Barcelona Supercomputing Center and Nostrum Biodiscovery
Yuan Wang, PhD, Head of Research Analytics, UCB Pharma

• Use of molecular modeling and virtual screening for finding protein degraders
• Using deep learning, neural network analysis, and imaging for phenotypic drug discovery
• Using physics and computational chemistry to find inhibitors and allosteric modulators
• Using large language models to understand protein structures and novel drug modalities